2016 Society of Gynecologic Oncology Annual Meeting

Gynecologic Cancers
Issues in Oncology

Breaking Down Dogma With the Outgoing President of SGO

At the 2016 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, The ASCO Post sat down with the SGO’s outgoing President, Robert L. Coleman, MD, and discussed the revolutionary po...

Gynecologic Cancers

Roundup of Ovarian Cancer Abstracts From 2016 SGO Annual Meeting on Women’s Cancer

At the 2016 Society of Gynecologic Oncology’s (SOG’s) Annual Meeting on Women’s Cancer, Thomas J. Herzog, MD, Clinical Director, University of Cincinnati (UC) Cancer Institute and Professor of Obstetr...

Gynecologic Cancers

Intraperitoneal Chemotherapy in Question in Ovarian Cancers

A phase III trial of bevacizumab (Avastin) with intravenous vs intraperitoneal chemotherapy showed no improvement in progression-free survival for first-line treatment of patients with optimally surgi...

Gynecologic Cancers

Study Supports Initial Attempt at Debulking Surgery in Stage IIIC Ovarian, Fallopian Tube, and Peritoneal Carcinoma

In a study exploring the effect of primary debulking surgery in women with bulky stage IIIC ovarian, fallopian tube, and primary peritoneal cancers, cytoreduction to no gross residual disease was asso...

Gynecologic Cancers

Genetic Testing in Women With Ovarian Cancer Helps to Determine Prognosis

A new study suggests that homologous recombination deficiency may have significant prognostic implications for patients with ovarian cancer, highlighting the importance of genetic testing in this popu...

Gynecologic Cancers

Expert Point of View: Kathleen Moore, MD

Session moderator Kathleen Moore, MD, Associate Professor of Obstetrics and Gynecology at the University of Oklahoma College of Medicine, Oklahoma City, said that while the response rates are “not inc...

Gynecologic Cancers

Trabectedin Improves Progression-Free Survival in Uterine Leiomyosarcoma

In women with uterine leiomyosarcoma, trabectedin (Yondelis), a novel cytotoxic agent, significantly improved progression-free survival, compared with dacarbazine (4.2 vs 1.5 months, hazard ratio [HR]...

Advertisement

Advertisement



Advertisement

click me